HTG Molecular Diagnostics (NASDAQ:HTGM) released its quarterly earnings results on Thursday. The medical research company reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.15, Fidelity Earnings reports. The company had revenue of $7.90 million during the quarter, compared to analysts’ expectations of $7.05 million.
HTGM stock opened at $4.47 on Friday. HTG Molecular Diagnostics has a 12-month low of $1.59 and a 12-month high of $13.25.
Several research analysts recently commented on HTGM shares. HC Wainwright set a $6.00 price target on HTG Molecular Diagnostics and gave the stock a “buy” rating in a research report on Wednesday, December 27th. Canaccord Genuity boosted their target price on HTG Molecular Diagnostics to $5.00 in a research report on Friday, January 5th. Finally, Zacks Investment Research lowered HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $6.56.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.